{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:03:13Z","timestamp":1792292593721,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40265-018-1015-2","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T13:47:53Z","timestamp":1542980873000},"page":"1931-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Omadacycline: First Global Approval"],"prefix":"10.1007","volume":"78","author":[{"given":"Anthony","family":"Markham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"1015_CR1","unstructured":"Paratek Pharmaceuticals. Paratek announces FDA approval of NUZYRA\u2122 (omadacycline) (media release). 2 Oct 2018."},{"key":"1015_CR2","unstructured":"Paratek Pharmaceuticals. Paratek announces acceptance of European Marketing Authorization application for oral and intravenous omadacycline (media release). 4 Oct 2018."},{"key":"1015_CR3","unstructured":"Huband MD, Pfaller MA, Streit JM, et al. Omadacycline in vitro activity against skin and skin structure, respiratory, and urinary tract pathogens collected from the U.S. and Europe during the SENTRY Surveillance Program (2017). (abstract no. 627 plus poster). In: ASM Microbe 2018. 2018."},{"issue":"4","key":"1015_CR4","doi-asserted-by":"publisher","first-page":"e00047","DOI":"10.1128\/AAC.00047-18","volume":"62","author":"L Stapert","year":"2018","unstructured":"Stapert L, Wolfe C, Shinabarger D, et al. In vitro activities of omadacycline and comparators against anaerobic bacteria. Antimicrob Agents Chemother. 2018;62(4):e00047\u2013118.","journal-title":"Antimicrob Agents Chemother."},{"key":"1015_CR5","unstructured":"Paratek Pharmaceuticals. Nuzyra (omadacycline): US prescribing information. 2018. \n                    https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/209816_209817lbl.pdf\n                    \n                  . Accessed 23 Oct 2018."},{"key":"1015_CR6","unstructured":"Paratek Pharmaceuticals. Paratek, U.S. Department of Defense enter research agreement to study omadacycline against biodefense pathogens (media release). 11 Oct 2016."},{"key":"1015_CR7","unstructured":"Paratek Pharmaceuticals. Paratek Pharmaceuticals and Zai Lab announce collaboration, development and license agreement for omadacycline in China (media release). 24 Apr 2017."},{"key":"1015_CR8","unstructured":"Bayer AG, Bayer Pharmaceuticals Corporation, Paratek Pharmaceuticals Inc. Bayer and Paratek Pharmaceuticals sign collaboration agreement for the novel antibiotic BAY 73-6944\/PTK 0796 (media release). 15 Sep 2003."},{"key":"1015_CR9","unstructured":"Merck & Co. Inc., Paratek Pharmaceuticals Inc. Merck and Paratek Pharmaceuticals sign collaboration agreement for novel antibiotic PTK 0796 currently in phase 1 testing (media release). 9 Mar 2006."},{"key":"1015_CR10","unstructured":"Novartis. Novartis gains exclusive worldwide rights to PTK 0796, in phase III study as potential first-in-class IV and oral broad-spectrum antibiotic (media release). 8 Oct 2009."},{"issue":"24","key":"1015_CR11","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1016\/j.bmc.2016.07.029","volume":"24","author":"SK Tanaka","year":"2016","unstructured":"Tanaka SK, Steenbergen J, Villano S. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem. 2016;24(24):6409\u201319.","journal-title":"Bioorg Med Chem."},{"issue":"3","key":"1015_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1128\/AAC.01066-13","volume":"58","author":"MP Draper","year":"2014","unstructured":"Draper MP, Weir S, Macone A, et al. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother. 2014;58(3):1279\u201383.","journal-title":"Antimicrob Agents Chemother."},{"key":"1015_CR13","unstructured":"US Food and Drug Administration. Omadacycline injection and oral products: FDA identified breakpoints. 2018. \n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/ucm622612.htm\n                    \n                  . Accessed 9 Nov 2018."},{"issue":"5","key":"1015_CR14","doi-asserted-by":"publisher","first-page":"e02434","DOI":"10.1128\/AAC.02434-16","volume":"61","author":"J Steenbergen","year":"2017","unstructured":"Steenbergen J, Tanaka SK, Miller LL, et al. in vitro and in vivo activity of omadacycline against two biothreat pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017;61(5):e02434.","journal-title":"Antimicrob Agents Chemother."},{"key":"1015_CR15","doi-asserted-by":"crossref","unstructured":"Mendes R.E., Castangiera M., Armstrong E.S., et al. Efficacy of omadacycline against molecularly characterized Gram-positive and Gram-negative pathogens causing infections in the phase 3 CABP and ABSSSI clinical trials [abstract no. 1364 plus poster]. In: ID Week 2018. 2018.","DOI":"10.1093\/ofid\/ofy210.1195"},{"issue":"5","key":"1015_CR16","doi-asserted-by":"publisher","first-page":"05","DOI":"10.1128\/AAC.02368-16","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 2017;61(5):05.","journal-title":"Antimicrob Agents Chemother."},{"key":"1015_CR17","doi-asserted-by":"crossref","unstructured":"Lepak AJ, Zhao M, Marchillo K, et al. In vivo pharmacodynamic evaluation of Omadacycline (PTK 0796) against Staphylococcus aureus (SA) in the murine thigh infection model [abstract no. 1531]. OFID. 2017;4(Suppl. 1):S478\u20139.","DOI":"10.1093\/ofid\/ofx163.1227"},{"key":"1015_CR18","unstructured":"Bhavnani SM, Hammel JP, Lakota EA, et al. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia (CABP) for Streptococcus pneumoniae (Sp) and Haemophilus Influenzae (Hi) [abstract no. 3793]. In: ASM Microbe 2018. 2018."},{"key":"1015_CR19","doi-asserted-by":"crossref","unstructured":"Darpo B, Tzanis E, Garrity-Ryan L, et al. Cardiac safety of omadacycline in the IV\/oral phase 3 acute bacterial skin and skin structure infection (ABSSSI) and in the IV\/oral phase 3 community-acquired bacterial pneumonia (CABP) studies [abstract no. 1886]. OFID. 2017;4(Suppl.1):S544-S5.","DOI":"10.1093\/ofid\/ofx163.1416"},{"issue":"9","key":"1015_CR20","doi-asserted-by":"publisher","first-page":"e01135","DOI":"10.1128\/AAC.01135-17","volume":"61","author":"MH Gotfried","year":"2017","unstructured":"Gotfried MH, Horn K, Garrity-Ryan L, et al. Comparison of omadacycline and tigecycline pharmacokinetics in the plasma, epithelial lining fluid, and alveolar cells of healthy adult subjects. Antimicrob Agents Chemother. 2017;61(9):e01135\u2013217.","journal-title":"Antimicrob Agents Chemother."},{"key":"1015_CR21","unstructured":"Tanaka K, Tzanis E, Villano S. Effect of age and gender on the pharmacokinetics of the oral and IV omadacycline, a new class of aminomethylcyclines [abstract no. P1318 and poster]. In: 26th ECCMID. 2016."},{"issue":"2","key":"1015_CR22","first-page":"e02057","volume":"62","author":"JK Berg","year":"2018","unstructured":"Berg JK, Tzanis E, Garrity-Ryan L, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother. 2018;62(2):e02057\u2013117.","journal-title":"Antimicrob Agents Chemother."},{"key":"1015_CR23","doi-asserted-by":"crossref","unstructured":"Stets R, Popescu M, Gonong J, et al. A phase 3 randomized, double-blind, multi-center study to compare the safety and efficacy of IV-to-oral omadacycline to moxifloxacin for the treatment of adult subjects with CABP (The OPTIC Study) [abstract no. 1883 plus poster]. OFID. 2017;4(Suppl. 1):S543-S4.","DOI":"10.1093\/ofid\/ofx163.1413"},{"key":"1015_CR24","unstructured":"O\u2019Riordan WA, Green S, Overcash JS, et al. A phase 3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral and IV omadacycline to linezolid for treating adult subjects with ABSSSI (the OASIS study) [abstract no. OS0606 and oral presentation]. In: 27th ECCMID. 2017."},{"key":"1015_CR25","unstructured":"O\u2019Riordan W, Cardenas C, Sirbu A, et al. A phase-3 randomized, double-blind, multi-centre study to compare the safety and efficacy of oral omadacycline to oral linezolid for treating adult subjects with ABSSSI (OASIS-2 study) [abstract no. O0425]. In: 28th ECCMID. 2018."},{"issue":"11","key":"1015_CR26","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1128\/AAC.00948-12","volume":"56","author":"GJ Noel","year":"2012","unstructured":"Noel GJ, Draper MP, Hait H, et al. A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(11):5650\u20134.","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-1015-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-1015-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:16:20Z","timestamp":1574468180000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-1015-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":26,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-1015-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"23 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis\/Springer, and Susan Keam, an employee of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}